K
Keiji Fukuda
Researcher at Li Ka Shing Faculty of Medicine, University of Hong Kong
Publications - 99
Citations - 29021
Keiji Fukuda is an academic researcher from Li Ka Shing Faculty of Medicine, University of Hong Kong. The author has contributed to research in topics: Influenza A virus subtype H5N1 & Influenza A virus. The author has an hindex of 46, co-authored 95 publications receiving 27831 citations. Previous affiliations of Keiji Fukuda include United States Department of Agriculture & University of Hong Kong.
Papers
More filters
Journal ArticleDOI
Acyclovir-Resistant Genital Herpes Among Persons Attending Sexually Transmitted Disease and Human Immunodeficiency Virus Clinics
Michele Reyes,Nazerah S. Shaik,Judith M. Graber,Rosane Nisenbaum,Neal T. Wetherall,Keiji Fukuda,William C. Reeves +6 more
TL;DR: In the 15 years following licensure of acyclovir, resistance to the drug remains low among immunocompetent patients, however, 5% of HIV-positive patients had resistant HSV-2 isolates.
Journal ArticleDOI
Influenza A among Patients with Human Immunodeficiency Virus: An Outbreak of Infection at a Residential Facility in New York City
Anne D. Fine,Carolyn B. Bridges,Angel M. De Guzman,Louise Glover,Barbara Zeller,Susan J. Wong,Inger Baker,Helen L. Regnery,Keiji Fukuda +8 more
TL;DR: HIV infection was not statistically associated with influenza-like illness (ILI) and vaccination effectiveness was similar for HIV-infected and HIV-uninfected persons, and providers should continue to offer influenza vaccination to HIV- infected persons.
Journal ArticleDOI
Cruise ships: high-risk passengers and the global spread of new influenza viruses.
Joy M. Miller,Theresa W. S. Tam,Susan A. Maloney,Keiji Fukuda,Nancy J. Cox,James Hockin,Daniel A. Kertesz,Alexander Klimov,Martin S. Cetron +8 more
TL;DR: It is concluded that an "off-season" influenza outbreak occurred among international travelers and crew on board this cruise ship in 1997.
Journal ArticleDOI
Health benefits, risks, and cost-effectiveness of influenza vaccination of children.
Lisa A. Prosser,Carolyn B. Bridges,Timothy M. Uyeki,Virginia L. Hinrichsen,Martin I. Meltzer,Noelle-Angelique M. Molinari,Benjamin Schwartz,William W. Thompson,Keiji Fukuda,Tracy A. Lieu +9 more
TL;DR: Vaccinating children aged 6–23 months, plus all other children at high-risk, will likely be more effective than vaccinating all children against influenza.
Journal Article
Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP).
TL;DR: This report summarizes recommendations by the Advisory Committee on Immunization Practices (ACIP) for using intranasally administered, trivalent, cold-adapted, live, attenuated influenza vaccine (LAIV), which was approved for use in the United States on June 17, 2003.